Why the study?
Cardiovascular complications during cancer therapy are increasing due to vascular toxicity, necessitating improved early recognition and prevention of cardiac vascular toxicity.
Cancer therapies can induce significant vascular toxicity and coronary artery disease, necessitating careful baseline risk stratification and monitoring with multimodality cardiac imaging.
Raises awareness of coronary risks during cancer therapy; leaves open optimal management strategies.
Cardiovascular complications during chemotherapy and radiotherapy are becoming an increasing problem because many patients with cancer are treated with agents that exert significant vascular toxicity. Coronary heart disease in patients with cancer presents particular challenges, which directly impact the management of both the coronary disease and malignancy. Several chemotherapeutic agents have been shown to trigger ischemic heart disease, and as it has happened for myocardial cardiotoxicity, more attention should be dedicated to improving early recognition and prevention of cardiac vascular toxicity. Cardiac imaging could facilitate early detection of vascular toxicity, but a thorough risk stratification should always be performed to identify patients at higher risk of vascular impairment.
No takes yet. Share an insight, caveat, or question.
Dessalvi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: